Warning: CEPH International
Warning: CEPH International
On Sept. 13, the US Food and Drug Administration’s San Juan (PR) District office sent a warning letter to CEPH International Corp. (Caguas, PR), acquired by Patheon (Mississauga, ON, Canada) in 2004 in its purchase of Mova Corporation. The letter, posted on FDA’s Web site on Sept. 27, cites the facility for failing to control and correct out-of-specification fill weights for certain versions of the "Omnicef OP" oral suspensions it manufactures under contract.
A Sept. 27 Patheon press release said, “As indicated in the Warning Letter, the affected product is powder for oral suspension, Omnicef OP 250 mg/5mL and 125 mg/5mL. The issues identified in the Warning Letter affect all manufacturing lines for the powder for oral suspension product. The capsule product is not affected.
“Patheon and CEPH are working diligently with their client to resolve the issues identified by the FDA in the Warning Letter. CEPH has decided to voluntarily suspend production of the powder product while it resolves these matters. Patheon and CEPH are committed to working expeditiously to resolve these issues so as to avoid interruption of supply of the product for the client."
–Douglas McCormick
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
